JP2014139220A5 - - Google Patents

Download PDF

Info

Publication number
JP2014139220A5
JP2014139220A5 JP2014061763A JP2014061763A JP2014139220A5 JP 2014139220 A5 JP2014139220 A5 JP 2014139220A5 JP 2014061763 A JP2014061763 A JP 2014061763A JP 2014061763 A JP2014061763 A JP 2014061763A JP 2014139220 A5 JP2014139220 A5 JP 2014139220A5
Authority
JP
Japan
Prior art keywords
patient
drug
administered
parathyroid hormone
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014061763A
Other languages
English (en)
Japanese (ja)
Other versions
JP6177718B2 (ja
JP2014139220A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014139220A publication Critical patent/JP2014139220A/ja
Publication of JP2014139220A5 publication Critical patent/JP2014139220A5/ja
Application granted granted Critical
Publication of JP6177718B2 publication Critical patent/JP6177718B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2014061763A 1998-08-19 2014-03-25 骨の靭性、及び、剛性を増し、骨折を減少させる方法 Expired - Lifetime JP6177718B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9715198P 1998-08-19 1998-08-19
US60/097,151 1998-08-19
US9974698P 1998-09-10 1998-09-10
US60/099,746 1998-09-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010244314A Division JP2011021035A (ja) 1998-08-19 2010-10-29 骨の靭性、及び、剛性を増し、骨折を減少させる方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014204577A Division JP2015028065A (ja) 1998-08-19 2014-10-03 骨の靭性、及び、剛性を増し、骨折を減少させる方法

Publications (3)

Publication Number Publication Date
JP2014139220A JP2014139220A (ja) 2014-07-31
JP2014139220A5 true JP2014139220A5 (enExample) 2014-09-25
JP6177718B2 JP6177718B2 (ja) 2017-08-09

Family

ID=26792729

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2000565916A Pending JP2002523375A (ja) 1998-08-19 1999-08-19 骨の靭性、及び、剛性を増し、骨折を減少させる方法
JP2010244314A Withdrawn JP2011021035A (ja) 1998-08-19 2010-10-29 骨の靭性、及び、剛性を増し、骨折を減少させる方法
JP2014061763A Expired - Lifetime JP6177718B2 (ja) 1998-08-19 2014-03-25 骨の靭性、及び、剛性を増し、骨折を減少させる方法
JP2014204577A Withdrawn JP2015028065A (ja) 1998-08-19 2014-10-03 骨の靭性、及び、剛性を増し、骨折を減少させる方法
JP2017124301A Withdrawn JP2017190332A (ja) 1998-08-19 2017-06-26 骨の靭性、及び、剛性を増し、骨折を減少させる方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2000565916A Pending JP2002523375A (ja) 1998-08-19 1999-08-19 骨の靭性、及び、剛性を増し、骨折を減少させる方法
JP2010244314A Withdrawn JP2011021035A (ja) 1998-08-19 2010-10-29 骨の靭性、及び、剛性を増し、骨折を減少させる方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014204577A Withdrawn JP2015028065A (ja) 1998-08-19 2014-10-03 骨の靭性、及び、剛性を増し、骨折を減少させる方法
JP2017124301A Withdrawn JP2017190332A (ja) 1998-08-19 2017-06-26 骨の靭性、及び、剛性を増し、骨折を減少させる方法

Country Status (32)

Country Link
US (2) US6977077B1 (enExample)
EP (3) EP2266598B1 (enExample)
JP (5) JP2002523375A (enExample)
KR (1) KR100454207B1 (enExample)
CN (1) CN1205997C (enExample)
AR (1) AR033639A1 (enExample)
AT (1) ATE231000T1 (enExample)
AU (1) AU746277B2 (enExample)
BR (1) BR9909445A (enExample)
CA (1) CA2325371C (enExample)
CO (1) CO5130020A1 (enExample)
CY (2) CY1113343T1 (enExample)
CZ (1) CZ301017B6 (enExample)
DE (2) DE15152726T1 (enExample)
DK (4) DK1769804T3 (enExample)
DZ (1) DZ2873A1 (enExample)
EA (1) EA003362B1 (enExample)
ES (4) ES2621653T3 (enExample)
HR (1) HRP20000755A2 (enExample)
HU (2) HU1200430D0 (enExample)
ID (1) ID29039A (enExample)
IL (2) IL138829A0 (enExample)
MY (1) MY129227A (enExample)
NO (2) NO323984B1 (enExample)
NZ (1) NZ507056A (enExample)
PE (1) PE20001089A1 (enExample)
PL (1) PL201688B1 (enExample)
PT (4) PT2266598T (enExample)
TR (1) TR200003455T2 (enExample)
TW (1) TW576747B (enExample)
UA (1) UA72205C2 (enExample)
WO (1) WO2000010596A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
AR033639A1 (es) 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
EP1222465A1 (en) * 1999-09-20 2002-07-17 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
JP2005525312A (ja) * 2002-01-10 2005-08-25 オステオトロフィン エルエルシー 骨同化物質を用いた骨疾患の治療方法
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
WO2005027915A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
RU2006143544A (ru) * 2004-05-10 2008-06-20 Нэстек Фармасьютикал Кампани Инк. (Us) Композиции и способ для облегченной чресслизистой доставки паратиреоидного гормона
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
AU2005244734A1 (en) 2004-05-13 2005-12-01 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
US7648965B2 (en) 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
WO2006073711A2 (en) 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
EP1879608A4 (en) * 2005-05-11 2009-11-11 Unigene Lab Inc METHOD FOR STIMULATING BONE FORMATION AND PRESERVATION
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
CN101355959B (zh) * 2005-11-10 2013-02-27 密歇根理工大学管理委员会 黑熊甲状旁腺素和使用黑熊甲状旁腺素的方法
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
PL2136850T3 (pl) 2007-04-13 2012-07-31 Kuros Biosurgery Ag Polimeryczny uszczelniacz tkankowy
US20110137243A1 (en) * 2007-09-06 2011-06-09 Abbott Cardiovascular Systems Inc. Coating On A Balloon Device
US9457056B2 (en) * 2007-12-04 2016-10-04 Ben-Gurion University Of The Negev Research And Development Authority Peptides comprising alternating hydrophobic and anionic amino acids for treatment of osteoporosis
WO2009083544A2 (en) 2007-12-28 2009-07-09 Kuros Biosurgery Ag Pdgf fusion proteins incorporated into fibrin foams
ES2663322T3 (es) * 2009-09-09 2018-04-12 Asahi Kasei Pharma Corporation Agente terapéutico/profiláctico que contiene PTH para la osteoporosis, caracterizado porque la PTH se administra una vez por semana en una dosis unitaria de 200 unidades
CA2782640A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9295663B2 (en) 2010-07-14 2016-03-29 Abbott Cardiovascular Systems Inc. Drug coated balloon with in-situ formed drug containing microspheres
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
WO2012123028A1 (en) 2011-03-16 2012-09-20 Kuros Biosurgery Ag Pharmaceutical formulation for use in spinal fusion
ES2833277T3 (es) 2011-06-07 2021-06-14 Asahi Kasei Pharma Corp Preparación liofilizada que contiene PTH de alta pureza y método para producirla
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EP3411066A1 (en) 2016-02-01 2018-12-12 Eli Lilly and Company Parathyroid hormone anti-rankl antibody fusion compounds
WO2018144719A1 (en) * 2017-02-01 2018-08-09 The Johns Hopkins University Parathyroid hormone and regeneration of degenerative discs disease
JP6577683B2 (ja) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
WO2020090174A1 (ja) 2018-10-29 2020-05-07 旭化成ファーマ株式会社 週２回の頻度でテリパラチド又はその塩を投与することを特徴とする、骨粗鬆症の予防又は治療方法
US12344649B2 (en) 2019-08-09 2025-07-01 Flagship Pioneering Innovations Vi, Llc Modulators of parathyroid hormone receptor (PTHR1)
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
IL78342A (en) 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE3935738A1 (de) 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5208041A (en) 1991-05-23 1993-05-04 Allelix Biopharmaceuticals Inc. Essentially pure human parathyroid hormone
CA2126299C (en) 1994-06-20 2000-12-12 Gordon E. Willick Parathyroid hormone analogues for the treatment of osteoporosis
JPH0873376A (ja) * 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
WO1996019246A1 (en) * 1994-12-19 1996-06-27 Beth Israel Hospital Association Continuous low-dose administration of parathyroid hormone or its agonist
EP0806945B1 (en) * 1994-12-22 2003-04-23 AstraZeneca AB Therapeutic preparation for inhalation containing parathyro d hormone, pth
JPH08310965A (ja) * 1995-05-16 1996-11-26 Chugai Pharmaceut Co Ltd 骨癒合促進剤
AU752925B2 (en) * 1997-09-09 2002-10-03 F. Hoffmann-La Roche Ag Fracture healing using PTHrP analogs
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
AR033639A1 (es) * 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
US6907597B1 (en) 2000-10-13 2005-06-14 Ati International Srl Method and apparatus for constructing an executable program in memory
US6967759B2 (en) 2001-12-31 2005-11-22 Texas Instruments Incorporated Pulse width modulation sequence generation
JP5796714B2 (ja) 2012-01-13 2015-10-21 株式会社リコー 定着装置及び画像形成装置
EP2949301B1 (en) 2014-05-27 2018-04-18 The Procter and Gamble Company Absorbent core with curved and straight absorbent material areas

Similar Documents

Publication Publication Date Title
JP2014139220A5 (enExample)
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
JP2017533972A5 (enExample)
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
NZ617397A (en) Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units
MY178445A (en) Novel antibody binding to tfpi and composition comprising the same
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
EP4578461A3 (en) Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
EP4700016A3 (en) Pharmaceutical agent for treating amyotrophic lateral sclerosis or suppressing disease progress thereof
JP2016509050A5 (enExample)
HK1255584A1 (zh) 使用阿坎酸及d-环丝胺酸的联合疗法
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
MX2020000164A (es) Formulaciones de isotretinoína para la mucosa oral y métodos para usar las mismas.
JOP20190019A1 (ar) تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
RU2020120156A (ru) Лечение приливов и потери костной ткани, вызванных андрогенной депривационной терапией с применением цис-кломифена
JP2019529569A5 (enExample)
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
EP4389218A3 (en) Composition for treating joint disease and kit containing same
PH12019502510A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو
MX2018013474A (es) Acidos carboxilicos para aplicacion en la primera infancia.
MX2020001217A (es) Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.